Pharmaceutical Technology
February 02, 2006
From The Editor
30
2
FDA is opening the door to continuous learning in process development.
February 02, 2006
Articles
30
2
LC–MS–MS has the potential to become a routine technique for determining drug residues in support of cleaning verification, especially early in drug development.
February 02, 2006
Articles
30
2
The pharmaceutical industry's focus on process understanding, monitoring, and control is driving manufacturers to take greater steps toward identifying possible manufacturing bottlenecks earlier in the development process. For tablet, capsule, and excipient producers, such efforts include taking a closer look at the flow-ability of their powders.
February 02, 2006
Agent-In-Place
30
2
"It was the late 1970s," reports our GMP-Agent-in-Place, "and we used a primitive desktop computer with built-in teletype for our quality control work.
February 02, 2006
This Time Around
30
2
I rarely talk science on the weekends. I spend a good deal of that free time with friends from college performance groups. The conversation centers more on choreography and piano concerti than on CGMPs and chemical reactions. So it always throws me for a loop when these theater and music buffs drop pharmaceutical news into casual conversation.
February 02, 2006
Articles
30
2
This is a year of change for the Synthetic Organic Chemical Manufacturers Association (SOCMA), the Washington, DC-based trade association representing chemical batch and custom manufacturers. Following the sale of Informex, its flagship trade show, last fall, the association is advancing key programs, most notably its new ChemStewards program, an environmental, health, safety, and security initiative (EHS&S) that its members began implementing last month.
February 02, 2006
Viewpoint
30
2
Enterprise information integration delivers needed real-time capability to operational business intelligence.
February 02, 2006
Washington Report
30
2
FDA is proposing revisions to the drug user fee program while it weighs changes for drug safety initiatives and expanded vaccine production.
February 02, 2006
Articles
30
2
The authors present an overview of various processes for producing nanoparticles and commercial nanoparticle technologies involved in the delivery of poorly water-soluble drugs.
February 02, 2006
In the Field
30
2
Preliminary results from a clinical trial of Sanofi Pasteur's (Lyon, France, www.sanofi.com) H5N1 prepandemic influenza vaccine indicate the vaccine is safe and was well-tolerated in 300 healthy volunteers. This study is the first trial of an H5N1 prepandemic influenza vaccine candidate that compared vaccines with and without adjuvants.
February 02, 2006
Articles
30
2
Using a novel automated microfilling system, the authors demonstrate that roller compaction followed by milling is a viable preprocessing technique for high-dose chemical-in-capsule dosage forms. The process results in higher bulk and tapped densities for drug substances compared with milling alone.
February 02, 2006
Outsourcing
30
2
CMOs face market realities and exit some businesses.